12:00 AM
 | 
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cromafiban: Phase II

CORR said that data from a 106-patient Phase II pharmacologic trial showed that cromafiban has properties not seen with other oral GPIIb/IIIa inhibitors (see BioCentury, Aug. 16). The compound had a 21-hour half life, which CORR...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >